| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 133, 661-667, Copyright © 1993 by Endocrine Society
ARTICLES |
PA Rittenhouse, AD Levy, Q Li, CL Bethea and LD Van de Kar
Department of Pharmacology, Boston University Medical Center, Massachusetts 02118.
These studies examined the hypothalamic site and receptor subtype mediating the serotonergic (5-HT) control of PRL secretion in conscious male rats. Initially, we characterized the pharmacology of the 5-HT releaser and 5-HT agonists that increase PRL release. Subsequently, we performed lesion experiments to locate the 5-HT receptors involved in PRL secretion. p-Chloroamphetamine, a 5-HT releaser, is postulated to enter serotonergic nerve terminals through the 5-HT uptake mechanism, which can be inhibited by fluoxetine. p-Chloroamphetamine (8 mg/kg, ip) increased the plasma PRL concentration approximately 6-fold. The 5-HT uptake inhibitor fluoxetine almost completely prevented this increase, demonstrating that p-chloroamphetamine increases PRL release via a serotonergic mechanism. The 5-HT1C/5-HT2 agonist +(-)-1-(2,5-dimethoxy- 4-iodophenyl)2-aminopropane HCl (ip) produced a strong (30-fold) dose- dependent elevation of plasma PRL, which was virtually eliminated by 0.1 mg/kg (sc) ritanserin, a 5-HT1C/5-HT2 antagonist. +(-)-1-(2,5- Dimethoxy-4-iodophenyl)2-aminopropane HCl injected intracerebroventricularly (icv) in doses below those that were peripherally effective also produced a significant (8-fold) increase in PRL secretion that was again attenuated by icv pretreatment with ritanserin (2 micrograms/kg). RU 24969 (5-methoxy-3-[1,2,3,4-tetrahydro- 4-pyridinyl]1H-indole) was reported to act as both a 5-HT releaser and a direct postsynaptic 5-HT agonist. To test whether RU 24969 releases 5- HT to increase PRL secretion, we depleted 5-HT stores with the 5-HT synthesis inhibitor p-chlorophenylalanine. The ability of RU 24969 (0.5, 1, 5, and 10 mg/kg, ip) to elevate PRL secretion was not inhibited by pretreatment with p-chlorophenylalanine, suggesting that RU 24969 stimulates PRL secretion only through activation of postsynaptic 5-HT receptors. To test whether RU 24969 acts centrally, it was injected either icv, through chronic icv cannulae, or peripherally (ip). RU 24969 injected icv significantly stimulated PRL secretion (11-fold) at doses 500-fold lower than the peripherally effective doses (10 micrograms/kg vs. 5 mg/kg), suggesting a role for central 5-HT receptors in the regulation of PRL secretion. In addition, rats pretreated with the 5-HT1C/5-HT2 antagonist LY53857 (icv) significantly inhibited the PRL response if RU 24969 was injected ip, but not icv. The results of these experiments suggest that 5-HT1C or 5- HT2 receptors in the brain participate in the serotonergic stimulation of PRL secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
![]() |
A. T Strachan, J. B Leiper, and R. J Maughan Paroxetine administration to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environment Exp Physiol, November 1, 2004; 89(6): 657 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Damjanoska, N. A. Muma, Y. Zhang, D. N. D'Souza, F. Garcia, G. A. Carrasco, G. H. Kindel, K. A. Haskins, M. Shankaran, B. R. Petersen, et al. Neuroendocrine Evidence That (S)-2-(Chloro-5-fluoro-indol- l-yl)-1-methylethylamine Fumarate (Ro 60-0175) Is Not a Selective 5-Hydroxytryptamine2C Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1209 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, K. J. Damjanoska, G. A. Carrasco, B. Dudas, D. N. D'Souza, J. Tetzlaff, F. Garcia, N. R. S. Hanley, K. Scripathirathan, B. R. Petersen, et al. Evidence That 5-HT2A Receptors in the Hypothalamic Paraventricular Nucleus Mediate Neuroendocrine Responses to (-)DOI J. Neurosci., November 1, 2002; 22(21): 9635 - 9642. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Van de Kar, A. Javed, Y. Zhang, F. Serres, D. K. Raap, and T. S. Gray 5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells J. Neurosci., May 15, 2001; 21(10): 3572 - 3579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mas, M. Farré, R. de la Torre, P. N. Roset, J. O. J. Segura, and J. Camí Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 136 - 145. [Abstract] [Full Text] |
||||
![]() |
L. D. V. d. Kar, Q. Li, T. M. Cabrera, M. S. Brownfield, and G. Battaglia Alterations in 8-Hydroxy-2-(dipropylamino)tetralin-Induced Neuroendocrine Responses after 5,7-Dihydroxytryptamine-Induced Denervation of Serotonergic Neurons J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 256 - 262. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |